1-8 of 8
Jukka Vakkila, MD PhD
Close
Sort by
Journal Articles

Low Epression of MiR-18a Distinguishes Pediatric and Adult Acute Lymphoblastic Leukemia from Each Other

Neda Mosakhani, MD PhD, Mohamed El Missiry, MD MSc, Emmi Vakkila, MDcal student, Päivi Heikkilä, MD PhD, Sakari Knuutila, PhD, Jukka Vakkila, MD PhD
Journal: Blood
Blood (2015) 126 (23): 4991.
https://doi.org/10.1182/blood.V126.23.4991.4991
Published: 2015
Journal Articles

Functional Characterization of T- and NK-Cells in Chronic Myeloid Leukemia Patients Treated with Interferon-α Monotherapy.

Mette Matilda Ilander, MSc, Anna Kreutzman, PhD, Peter Rohon, MD, Teresa Melo, MD, Edgar Faber, MD, PhD, Kimmo Porkka, MD, PhD, Jukka Vakkila, MD, PhD, Satu Mustjoki, MD, PhD
Journal: Blood
Blood (2012) 120 (21): 2782.
https://doi.org/10.1182/blood.V120.21.2782.2782
Published: 2012
Journal Articles

Dasatinib Has a Dual Mode of Action: Direct BCR-ABL1 Mediated Anti-Leukemic Effects Are Complemented by Promotion of Th1-Type and NK-Cell Mediated Cellular Immune Responses,

Anna Kreutzman, MSc, Jukka Vakkila, MD, PhD, Kimmo Porkka, MD, PhD, Satu Mustjoki, MD, PhD
Journal: Blood
Blood (2011) 118 (21): 3760.
https://doi.org/10.1182/blood.V118.21.3760.3760
Published: 2011
Journal Articles

Dasatinib Induces a Rapid, Dose-Controllable Mobilization of Cytotoxic Lymphocytes: A Novel Immunomodulatory Effect Associated with Prolonged Therapy Responses In Advanced Leukemia.

Satu Mustjoki, MD, PhD, Philippe Rousselot, MD, PhD, Sari Jalkanen, Msc, Anna Kreutzman, MSc, Teresa Melo, MD, Anna-Maria Lahesmaa, MSc, Sampsa Hautaniemi, PhD, Mathieu Molimard, MD, PhD, Richard Smykla, PhD, Francis Lee, PhD, Jukka Vakkila, MD, PhD, Kimmo Porkka, MD, PhD
Journal: Blood
Blood (2010) 116 (21): 1204.
https://doi.org/10.1182/blood.V116.21.1204.1204
Published: 2010
Journal Articles

Cytokine-Mediated Signaling Is Suppressed in Myeloid Cells and Enhanced in Lymphatic Cells in Patients with Chronic Myeloid Leukemia (CML) — Partial Normalization with Tyrosine Kinase Inhibitors.

Sari Jalkanen, MSc, Satu Mustjoki, MD, PhD, Kimmo Porkka, MD, PhD, Jukka Vakkila, MD, PhD
Journal: Blood
Blood (2009) 114 (22): 2180.
https://doi.org/10.1182/blood.V114.22.2180.2180
Published: 2009
Journal Articles

Clonal Expansion of T/NK-Cells during Tyrosine Kinase Inhibitor Dasatinib Therapy

Satu Mustjoki, MD, PhD, Marja Ekblom, MD, PhD, T. Petteri Arstila, MD, PhD, Ingunn Dybedal, MD, PhD, PK Epling- Burnette, PhD, Felix Garzon, MD, PhD, Tobias Gedde-Dahl, MD, PhD, Sari Hernesniemi, MSc, Henrik Hjorth-Hansen, MD, PhD, Martin Hoglund, MD, PhD, Vesa Juvonen, PhD, Veli Kairisto, MD, PhD, Panu Kovanen, MD, PhD, Anna Kreutzman, MSc, Tuisku Laurinolli, Jane Liesveld, MD, Ronald Paquette, MD, Javier Pinilla, MD, PhD, Auvo Rauhala, MD, PhD, Neil Shah, MD, PhD, Bengt Simonsson, MD, PhD, Marjatta Sinisalo, MD, PhD, Juan Luis Steegmann, MD, PhD, Leif Stenke, MD, PhD, Jukka Vakkila, MD, PhD, Kimmo Porkka, MD, PhD
Journal: Blood
Blood (2008) 112 (11): 573.
https://doi.org/10.1182/blood.V112.11.573.573
Published: 2008
Journal Articles

Single-Cell Profiling of Aberrant Cytokine Signaling in Patients with Chronic Myeloid Leukemia (CML) at Diagnosis and during Dasatinib Therapy

Sari Hernesniemi, Jukka Vakkila, MD, PhD, Kimmo Porkka, MD, PhD, Satu Mustjoki, MD, PhD
Journal: Blood
Blood (2008) 112 (11): 4214.
https://doi.org/10.1182/blood.V112.11.4214.4214
Published: 2008
Journal Articles

Imatinib Discontinuation Following a Major Molecular Response: Impact of Interferon Alpha and Leukemia Stem Cell Burden (The STOP Study).

Perttu Koskenvesa, MD, Satu Mustjoki, MD, PhD, Anu Räsänen, MD, Mirja Vapaatalo, MD, Kari Remes, MD, PhD, Tuija Lundán, MSc, PhD, Jukka Vakkila, MD, PhD, Bengt Simonsson, MD, PhD, Kimmo Porkka, MD, PhD
Journal: Blood
Blood (2008) 112 (11): 2121.
https://doi.org/10.1182/blood.V112.11.2121.2121
Published: 2008